Antibody-Drug Conjugate: Linker Stability And Catabolites

Pharmaron poster on Antibody-Drug Conjugate profiling outlines a systematic in vitro catabolism approach with structural diagrams and data tables.

Poster Authors:

Shuyao Zheng, Guoqing Shen, Wenxia Tian, Junyan Li, Yuezhu Zang, Mandy Xu

Antibody-drug conjugate development requires early insight into how linkers and payloads behave under metabolic stress. By profiling catabolic stability and monitoring catabolite formation, researchers can better predict safety, efficacy and regulatory outcomes. This systematic approach ensures ADCs are both stable in circulation and effective at the tumor site.

Enhancing ADC Development Through In Vitro Catabolic Analysis

Early characterization of antibody-drug conjugates (ADCs) is critical for understanding their safety, efficacy and regulatory readiness. Pharmaron’s integrated in vitro platform assesses catabolic stability, linker-payload stability, and catabolite formation using enzyme-based incubation systems and high-resolution mass spectrometry. This method strengthens IND submissions and supports ADC de-risking by predicting metabolic behavior across species and confirming the specificity of linker cleavage.

A Structured Method for Investigating ADC Catabolism

To address regulatory guidance from agencies like the FDA and EMA, Pharmaron developed a systematic in vitro approach that simulates lysosomal conditions using:

Cathepsin B enzyme
Liver lysosomes
Liver S9 fraction

These models help predict linker cleavage, measure catabolite profiles and ensure the linker-payload remains stable in systemic circulation but active in tumor microenvironments.

Capabilities

Knowledge Center

DMPK Services

Antibody-drug Conjugates

Antibody Drug Conjugate Services

Discovery in vitro ADMET

Connect with a Scientific Expert

Complete the form to access resource

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.

Validating Linker Stability and Catabolite Formation

Studies using disitamab vedotin and ado-trastuzumab emtansine demonstrated distinct catabolite profiles associated with cleavable and non-cleavable linker technologies. Complete cleavage of the Val-Cit linker in disitamab vedotin led to rapid MMAE release, whereas the non-cleavable MCC linker in ado-trastuzumab emtansine produced characteristic DM1-containing catabolites.

High-resolution MS identified multiple catabolites, including key species like:

Lys-MCC-DM1
Tyr-MCC-DM1
MCC-DM1
DM1

Across mouse, monkey and human lysosomal systems, species-specific patterns were observed—reinforcing the value of comparative in vitro modeling.

Regulatory and Preclinical Impact

This profiling strategy addresses common challenges in ADC development:

Confirms linker-payload stability in circulation
Maps species differences in metabolic fate
Detects off-target degradation that may impact safety
Supports regulatory documentation through precise in vitro data

Download the complete poster to learn how our ADC profiling methods help streamline preclinical development and regulatory confidence.

References: